Mapping the Research of Ferroptosis in Parkinson’s Disease from 2013 to 2023: A Scientometric Review
Yingfan Chen,
No information about this author
Zhenhui Wu,
No information about this author
Shaodan Li
No information about this author
et al.
Drug Design Development and Therapy,
Journal Year:
2024,
Volume and Issue:
Volume 18, P. 1053 - 1081
Published: April 1, 2024
Methods:
Related
studies
on
PD
and
ferroptosis
were
searched
in
Web
of
Science
Core
Collection
(WOSCC)
from
inception
to
2023.
VOSviewer,
CiteSpace,
RStudio,
Scimago
Graphica
employed
as
bibliometric
analysis
tools
generate
network
maps
about
the
collaborations
between
authors,
countries,
institutions
visualize
co-occurrence
trends
co-cited
references
keywords.
Results:
A
total
160
original
articles
reviews
related
retrieved,
produced
by
958
authors
162
institutions.
Devos
David
was
most
prolific
author,
with
9
articles.
China
University
Melbourne
had
leading
positions
publication
volume
84
12
publications,
respectively.
Current
hot
topics
focus
excavating
potential
new
targets
for
treating
based
gaining
insight
into
specific
molecular
mechanisms,
including
iron
metabolism
disorders,
lipid
peroxidation,
imbalanced
antioxidant
regulation.
Clinical
aimed
at
targeting
remain
their
preliminary
stages.
Conclusion:
continued
increase
shown
literature
within
field
over
past
decade.
The
current
study
suggested
active
among
Research
pathogenesis
treatment
has
remained
a
prominent
topic
recent
years,
indicating
that
ferroptosis-targeted
therapy
is
approach
halting
progression
PD.
Keywords:
Parkinson's
disease,
ferroptosis,
analysis,
accumulation,
alpha-synuclein,
mitochondrial
dysfunction,
oxidative
stress,
peroxidation
Language: Английский
Do oral antidiabetic medications alter the risk of Parkinson’s disease? An updated systematic review and meta-analysis
Yanna Xie,
No information about this author
Jialiang Wang,
No information about this author
Jie Jiang
No information about this author
et al.
Neurological Sciences,
Journal Year:
2023,
Volume and Issue:
44(12), P. 4193 - 4203
Published: July 27, 2023
Language: Английский
CSF GPNMB in Parkinson's disease: A potential association with age and microglial activation
Journal of Parkinson s Disease,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 8, 2024
Recent
evidence
suggests
a
link
between
glycoprotein
non-metastatic
melanoma
protein
B
(GPNMB)
and
Parkinson's
disease
(PD)
pathogenesis.
Although
elevated
plasma
GPNMB
levels
associated
with
severity
have
been
reported
in
PD,
cerebrospinal
fluid
(CSF)
alterations
remain
elusive.
To
explore
CSF
its
clinical
significance
PD.
This
study
enrolled
118
sporadic
PD
patients
40
controls.
We
examined
the
potential
associations
characteristics
or
biomarkers
of
neurodegenerative
had
higher
than
controls
(p
=
0.0159).
In
group,
correlated
age
(age
at
examination:
rs
0.2511,
p
0.0061;
onset:
0.2800,
0.0021)
motor
cognitive
dysfunction
(MDS-UPDRS
III
score:
0.1998,
0.0347;
Mini-Mental
State
Examination
-0.1922,
0.0370).
After
correcting
for
multiple
comparisons,
correlation
onset
remained
significant.
were
also
positively
soluble
triggering
receptor
expressed
on
myeloid
cells
2
(sTREM2)
both
(rs
0.3582,
<
0.0001)
control
0.4743,
0.0023)
groups.
Furthermore,
regression
analysis
revealed
sTREM2
level
as
strongest
determinant
group
(t-value
3.49,
0.0007).
Elevated
levels,
linked
microglial
activation,
may
be
valuable
marker
understanding
interplay
aging,
neuroinflammation,
pathology.
Language: Английский